Current and future pharmacologic treatment of nonalcoholic steatohepatitis.

ABSTRACT:

Purpose of review

Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD), can progress to cirrhosis and hepatocellular cancer in 5-15% of patients and is rapidly becoming the leading cause for end-stage liver disease. Dietary caloric restriction and exercise, currently the cornerstone of therapy for NAFLD, can be difficult to achieve and maintain, underscoring the dire need for pharmacotherapy. This review presents the agents currently used in managing NAFLD and their pharmacologic targets. It also provides an overview of NAFLD agents currently under development.

Recent findings

Therapies for NASH can be broadly classified into agents that target the metabolic perturbations driving disease pathogenesis (such as insulin resistance

SUBMITTER: Banini BA 

PROVIDER: S-EPMC5491795 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature